



Universiteit  
Leiden  
The Netherlands

## Pharmacological aspects of corticotrophinergic and vasopressinergic function tests for HPA axis activation

Jacobs, G.E.

### Citation

Jacobs, G. E. (2010, December 15). *Pharmacological aspects of corticotrophinergic and vasopressinergic function tests for HPA axis activation*. Retrieved from <https://hdl.handle.net/1887/16245>

Version: Corrected Publisher's Version  
[Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)  
License:  
Downloaded from: <https://hdl.handle.net/1887/16245>

**Note:** To cite this publication please use the final published version (if applicable).

PHARMACOLOGICAL ASPECTS OF CORTICOTROPHINERGIC AND  
VASOPRESSINERGIC FUNCTION TESTS FOR HPA AXIS ACTIVATION



# **PHARMACOLOGICAL ASPECTS OF CORTICOTROPHINERGIC AND VASOPRESSINERGIC FUNCTION TESTS FOR HPA AXIS ACTIVATION**

## **PROEFSCHRIFT**

ter verkrijging van de graad van Doctor aan de Universiteit Leiden,  
op gezag van de Rector Magnificus prof. mr. P.F. van der Heijden,  
volgens besluit van het College voor Promoties,  
te verdedigen op woensdag 15 december 2010,  
klokke 10: 00 uur

door  
Gabriël Etienne Jacobs,  
geboren te Vereeniging, Zuid-Afrika  
in 1977

## **PROMOTIECOMMISSIE**

### **PROMOTORES**

Prof. dr. J.M.A. van Gerven

Prof. dr. F.G. Zitman

Prof. dr. A.F. Cohen

### **OVERIGE LEDEN**

Prof. dr. E.R. de Kloet

Prof. dr. H. Pijl

Dr. H.J. Gijsman, psychiater, opleider psychiatrie, GGZ Nijmegen

### **DESIGN**

Caroline de Lint, Voorburg (caro@delint.nl)

### **ACKNOWLEDGEMENTS**

The publication of this thesis was financially supported by the foundation Centre for Human Drug Research (CHDR), Leiden, the Netherlands

9	<b>CHAPTER 1</b> Introduction
35	<b>CHAPTER 2</b> Desmopressin as a pharmacological tool in vasopressinergic hypothalamus–pituitary–adrenal (HPA) axis modulation: neuroendocrine, cardiovascular and coagulatory effects
57	<b>CHAPTER 3</b> A pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis more integrally in healthy volunteers
77	<b>CHAPTER 4</b> Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa
99	<b>CHAPTER 5</b> Enhanced tolerability of the 5-hydroxytryptophane challenge test combined with granisetron
117	<b>CHAPTER 6</b> Metoclopramide as pharmacological tool to assess vasopressinergic co-activation of the hypothalamus–pituitary–adrenal (HPA) axis: A study in healthy volunteers
141	<b>CHAPTER 7</b> Hypothalamic glutamate levels following serotonergic stimulation: A pilot study using 7-Tesla magnetic resonance spectroscopy in healthy volunteers
163	<b>CHAPTER 8</b> General discussion and conclusions
180	Samenvatting / Summary in Dutch
189	Curriculum Vitae
191	Nwoord
192	List of publications



LIST OF ABBREVIATIONS

5-HT	5-hydroxytryptamine; serotonin	MRS	Proton Magnetic Resonance spectroscopy
5-HTP	5-hydroxytryptophan	NAA	N-acetyl-aspartate
7T	7-Tesla	NA	Noradrenaline
ACTH	Adreno-corticotrophic hormone	NRI	Noradrenaline reuptake inhibitor
ADH	Antidiuretic hormone	OGTT	Oral glucose tolerance test
AE	Adverse event	PD	Pharmacodynamic
ANCOVA	Analysis of covariance	PK	Pharmacokinetic
ANS	Autonomic nervous system	POMC	Pro-opiomelanocortin
ATD	Acute tryptophan depletion	PTSD	Post-traumatic stress disorder
AUC	Area under the plasma drug concentration-time curve	PVN	Paraventricular nucleus
AVP	Arginine-vasopressin	SAM	Sympatho-adrenal-medullary
BBB	Blood-brain-barrier	SBP	systolic blood pressure
BOLD	Blood oxygen level dependent	SCL-90	symptoms check List
CAMP	Cyclic adenosine monophosphate	SSRI	selective serotonin Reuptake Inhibitor
CAR	Cortisol awakening response	SON	supraoptic nucleus
CBD	Carbidopa	STEAM mode	single voxel stimulated echo acquisition mode
CHDR	Centre for Human Drug Research	T <sub>1/2</sub>	Elimination half life
Chol	choline	TCA	Tricyclic antidepressant drug
CL	Total clearance of drug from plasma	TE	Echo time
CNS	Central nervous system	THC	Tetrahydrocannabinol
CORT	Cortisol	T <sub>MAX</sub>	Time to maximal plasma drug concentration
C <sub>MAX</sub>	Maximal mean plasma concentration	TM	Mixing time
creat	Creatine	TR	Repetition time
CRH <sub>1</sub>	CRH <sub>1</sub> receptor	TSST	Trier social stress test
CRH	Corticotrophin-releasing hormone	V <sub>2</sub>	vasopressin-2 receptor
CTZ	Chemoreceptor trigger zone	V <sub>3</sub>	vasopressin-3 receptor
D <sub>2</sub>	Dopamine-2 receptor	VAS	visual analogue scale
DA	Dopamine	VOI	volume-of-interest
DBP	Diastolic blood pressure	VWF	von Willebrand factor
dDAVP	Desmopressin		
DEX	Dexamethasone		
DEX/CRH	Dexamethasone/corticorelin test		
ECG	Electrocardiogramme		
fMRI	Functional Magnetic Resonance Imaging		
GABA	γ-aminobutyric acid		
Glx	Glutamate/glutamine		
GR	Glucocorticoid receptor		
HR	Heart rate		
hCRH	Corticorelin		
HPA	Hypothalamus-pituitary-adrenal		
LSM	Least squared means		
LUMC	Leiden University Medical centre		
mCPP	m-chlorophenylpiperazine		
MAOI	Mono-amine oxidase inhibitor		
MCP	Metoclopramide		
MDD	Major depressive disorder		
MDMA	3,4-methylenedioxymethamphetamine		
MPFC	Medial prefrontal cortex		
MR	Mineralocorticoid receptor		
mRNA	Messenger ribonucleic acid		

